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SUMMARY
Enhanced mesenchymal expression of FGF10 led to the formation of multifocal PIN or prostate can-
cer. Inhibition of epithelial FGFR1 signaling using DN FGFR1 led to reversal of the cancer phenotype.
A subset of the FGF10-induced carcinoma was serially transplantable. Paracrine FGF10 led to an
increase in epithelial androgen receptor and synergized with cell-autonomous activated AKT. Our
observations indicate that stromal FGF10 expressionmay facilitate themultifocal histology observed
in prostate adenocarcinoma and suggest the FGF10/FGFR1 axis as a potential therapeutic target in
treating hormone-sensitive or refractory prostate cancer. We also show that transient exposure to
a paracrine growth factor may be sufficient for the initiation of oncogenic transformation.INTRODUCTION
The multifocal nature of human prostate cancer is elusive,
and mechanisms accounting for this histologic presenta-
tion are poorly understood. It is not uncommon to identify
areas of cancer adjacent to PIN and even normal prostate
tubules in human prostatectomy specimens. This degree
of heterogeneity has resulted in the Gleason scoring sys-
tem, which grades the histologic severity of representative
sections as a prognostic indicator of clinical behavior
(Bostwick and Foster, 1999).
Heterogeneous genetic instability in the glandular
epithelium due to telomerase shortening or infection with572 Cancer Cell 12, 572–585, December 2007 ª2007 Elsevierviruses such as BK, JC, and a recently described retroviral
isolate are two mechanisms by which multifocal disease
can occur (Das et al., 2004; Dong et al., 2007; Vukovic
et al., 2003; Zambrano et al., 2002). Another widely pro-
posed theory that may explain this multifocal heterogene-
ity is ‘‘field effect,’’ implicating global changes in the pros-
tate that can subsequently give rise to independent
polyclonal foci of disease (Harding and Theodorescu,
2000). Perturbations in the stroma may provide a mecha-
nism by which a global cancer-initiating microenvironment
can be instigated (Harding and Theodorescu, 2000).
Interactions between stroma and epithelium are critical
for development, and alterations in this homeostaticSIGNIFICANCE
Mechanisms underlying the multifocal nature of human prostate cancer are poorly understood. Using an in vivo
reconstitution system that relies on epithelial-stromal interactions, we show that enhanced expression of mesen-
chymal FGF10, an essential gene for prostate development, led to the formation of well-differentiated, multifocal
prostate adenocarcinoma. Paracrine FGF10 signaling caused intrinsic changes in adjacent adult wild-type epithe-
lium, demonstrated by an increase in epithelial androgen receptor (AR) expression, and the development of hor-
mone-refractory disease. FGF10-induced prostatic intraepithelial neoplasia (PIN) or adenocarcinoma could per-
sist in an FGF10-low microenvironment, likely as a result of sustained epithelial changes that evade chronic
dependence on this growth factor. We demonstrate a mechanism for the formation of multifocal prostate cancer.Inc.
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Zeisberg, 2006). Stromal cells are key regulators of adja-
cent epithelium in multiple epithelial tumor models such
as mammary gland (Cheng et al., 2005), skin (Seftor et al.,
2005), prostate (Bhowmick et al., 2004a; Hill et al., 2005),
and stomach cancers (Bhowmick et al., 2004a). In the nor-
mal setting and in these cancer models, epithelial control
is exerted by paracrine influences of the adjacent stroma.
Paracrine factors stimulate growth and expand the adja-
cent epithelia by interacting with transforming growth fac-
tor b (TGF-b), fibroblast growth factor (FGF), epidermal
growth factor (EGF), and insulin-like growth factor (IGF)
family receptors (Bhowmick et al., 2004b).
The FGF receptor (FGFR) signaling cascade exemplifies
the importance of epithelial and mesenchymal paracrine
crosstalk through a diverse set of ligands and receptors
that are compartmentalized in the stroma or epithelium
(Powers et al., 2000). FGF10 is predominantly expressed
in the mesenchyme of the developing prostate gland
and is an essential gene for prostate development (Donja-
cour et al., 2003). In vitro data suggest that FGF10 has
mitogenic actions on prostate epithelium and not stroma
(Thomson and Cunha, 1999). FGF10 binds preferentially
to the IIIb isoform of FGFR1 and FGFR2 (Kwabi-Addo
et al., 2004; Lu et al., 1999). Both of these receptors are
expressed in the normal prostate epithelium (Kwabi-
Addo et al., 2004; Lin et al., 2007; Lu et al., 1999).
Several lines of evidence indicate that altered expression
of the FGF/FGFR signaling axis may be important in pros-
tate pathology. FGF10 transcripts have been detected in
stroma derived from benign human prostatic hyperplasia
specimens (Nakano et al., 1999). A thorough analysis of
FGF10 expression is lacking in human prostate cancer. In
the Dunning rat tumor model, FGF10 expression has
been detected in the stroma and not epithelium of well-dif-
ferentiated tumors (Lu et al., 1999). Increased expressionof
FGFR1 is seen in both human prostate cancer and animal
models, such as TRAMP tumors with progression to poorly
differentiated adenocarcinoma (Huss et al., 2003; Sahade-
van et al., 2007). The role of FGFR2 in prostate cancer is de-
pendent on the expression of its specific isoform (Kwabi-
Addo et al., 2004). Activation of the FGFR2 IIIb isoform,
the binding partner for FGF10, is thought to have a role in
maintaining prostatic epithelial homeostasis, and overex-
pression of this receptor in neoplastic cells can restore
differentiation (Feng et al., 1997; Matsubara et al., 1998).
Previous studies have investigated the role of FGFR1
and FGFR2 in the progression of prostate cancer (Free-
man et al., 2003). In a transgenic mouse model, activation
of FGFR1 led to formation of PIN, while activation of
FGFR2 caused no discernable phenotype (Freeman et al.,
2003). Autocrine epithelial overexpression of FGF7, also
a stromal gene and a homolog of FGF10, in a transgenic
animal model led to the formation of prostate hyperplasia
after 1 year (Foster et al., 2002). These models used epi-
thelial-based FGF expression and did not promote FGF
signaling from the mesenchyme. As such, they do not
examine the role of mesenchymal FGF on adjacent epithe-
lial biology.CanWe set out to test whether enhanced expression of
mesenchymal FGF10 would be sufficient to drive transfor-
mation of adult prostate epithelium. We hypothesized that
the mitogenic paracrine effects of FGF10 could be
regional and predominantly on the neighboring epithelial
cells. To investigate the potential biologic effects of
FGF10-mediated signaling in the development of prostate
cancer, we used a tissue recombination prostate regener-
ation system (Cunha and Lung, 1978), further modified
into a dissociated single-cell reconstitution method (Xin
et al., 2003). In this model, adult dissociated prostate ep-
ithelial cells are combined with embryonic urogenital sinus
mesenchyme (UGSM) and grafted under the kidney cap-
sule of a SCID mouse, resulting in formation of prostate
gland-like structures (Xin et al., 2003). This model allows
for genetic manipulation of both compartments of the
prostate gland, the epithelium and the mesenchyme, inde-
pendently and, in contrast to previously published trans-
genic animal models, enables us to study the effects of
paracrine factors on adult prostate epithelial cells.
We show that enhanced expression of mesenchymal
FGF10 was sufficient for the formation of well-differenti-
ated prostate carcinoma. The disease pattern observed
was multifocal and similar to human prostate cancer
when the number of FGF10-expressing UGSM cells was
diluted. Inhibition of FGFR1 signaling with dominant-neg-
ative (DN) FGFR1 could reverse the neoplastic phenotype
even in the presence of excess mesenchymal FGF10.
Paracrine FGF10 led to an increase in epithelial androgen
receptor, and upon castration, FGF10 induced androgen-
independent survival and proliferation. FGF10-induced
PIN or adenocarcinoma persisted in an FGF10-low micro-
environment, with sustained activation of the AR machin-
ery. Paracrine FGF10 synergized with cell-autonomous
activated AKT and resulted in the formation of poorly
differentiated adenocarcinoma.
RESULTS
Paracrine Signaling Mediated by Mesenchymal
FGF10 Is Sufficient for the Histologic
Transformation of the Adjacent
Prostate Epithelium
Retroviral constructs were designed to express GFP or
FGF10 and GFP (Figure S1A in the Supplemental Data
available with this article online). UGSM was infected
with either control vector (GFP) or FGF10-GFP retrovirus.
Expression of secreted FGF10 was confirmed by western
blot (Figure S1B). FACS analysis confirmed greater than
90% infection of the UGSM cells (Figure S1C).
Dissociated adult murine prostate cells (1 3 105) were
combined with UGSM cells (1 3 105) infected either with
control or FGF10-expressing vectors and engrafted under
the kidney capsule of CB.17 SCID/SCID mice (Xin et al.,
2003). After 8 weeks, mice were sacrificed, and grafts
were dissected off the kidney (Figure 1A). The FGF10-
expressing grafts weighed greater than twice the control
grafts (Figure 1A).cer Cell 12, 572–585, December 2007 ª2007 Elsevier Inc. 573
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Stromal FGF10-Induced Multifocal Prostate CancerFigure 1. Paracrine FGF10 Expression Led to Well-Differentiated Adenocarcinoma and an Expansion of Both Luminal and Basal
Cells
(A) Transilluminating image and weight (mean ± SD) of regenerated tissue from wild-type epithelia (13 105) combined with GFP- or FGF10-expressing
mesenchyme (1 3 105) placed in the regeneration system.
(B) H&E analysis of FGF10 UGSM- and GFP UGSM-regenerated tissue.
(C) High-power (10003) magnification of FGF10-induced adenocarcinoma demonstrating atypical (arrow) or large nuclei (arrow and asterisk) in (Ca)
and evidence of mitotic figures (arrow) in (Cb).
(D) Immunohistochemical analysis of the regenerated tissue using antibodies against E-cadherin, CK5, and P63.Histologic analysis of the control grafts revealed epithe-
lial glands two layers thick with abundant luminal secre-
tions (Figure 1B). In contrast, FGF10 grafts showed an
increased number of small glandular structures, one cell
layer thick, containing cells with increased nuclear to cyto-
plasmic ratios, prominent multiple nucleoli, scattered
apoptotic bodies, and occasional mitotic figures (Figures
1B and 1C). These features were diagnostic of well-differ-574 Cancer Cell 12, 572–585, December 2007 ª2007 Elsevier Ientiated prostate adenocarcinoma in 10/10 independent
paracrine FGF10-regenerated grafts (Figures 1B and 1C)
(Shappell et al., 2004). The commercially available anti-
bodies for FGF10 can not detect this protein by immuno-
histochemistry. Therefore, GFP faithfully expressed by an
internal ribosomal entry site (IRES) in the FGF10-express-
ing constructs was localized in the mesenchymal com-
partment of regenerated grafts (Figure S1D). Expressionnc.
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mesenchymal FGF10 (Figure S1D). The contour of the
epithelial cells was outlined by pancytokeratin staining
(Figure S1D). Enhanced expression of FGF10 was con-
firmed with western blot analysis in three independent
FGF10-regenerated grafts (Figure S1E).
To characterize the expanded epithelial cell population,
immunohistochemistry was performed for the epithelial
markers cytokeratin 5 (CK5), CK8, p63, and E-cadherin
(Figure 1D and Figure S2). Glands from FGF10 grafts
expressed E-cadherin (Figure 1D, top panel) and cytoker-
atin 8 (Figure S2A) confirming the epithelial nature of these
cells. We detected an approximately 3-fold expansion of
p63-positive cells in FGF10-expressing grafts (Figure 1D,
bottom panel). We also observed a dramatic expansion of
the luminal cells in FGF10 grafts compared to control
(Figure S2A). Paracrine FGF10 signaling resulted in the
formation of a glandular adenocarcinoma in a background
of prostatic hyperplasia. Previous models for prostate
cancer led to the formation of luminal or neuron-endocrine
carcinoma (Freeman et al., 2003; Greenberg et al., 1995;
Majumder et al., 2003; Wang et al., 2003). In our model
we observed an expansion of luminal cells expressing
CK8 (Figure S2A) in addition to an expansion of basal cells
expressing CK5/P63 (Figure S2B and Figure 1D, bottom
two panels).
Paracrine FGF10 Promotes Localized
Transformation in the Prostate
Regeneration System
We asked whether the transforming effects of FGF10 were
local or extended beyond the source of FGF10-secreting
cells. We placed one graft with FGF10-secreting UGSM
adjacent to a second graft with normal UGSM cells (Fig-
ure 2A). We then set up a dilution series of FGF10-secreting
cells such that the number of FGF10-secreting UGSM was
decreased in a logarithmic fashion by substituting normal
UGSM (Figure 2C). To measure the proliferation of regen-
erating epithelium at 6 weeks, mice were injected with bro-
modeoxyuridine (Brdu) i.p. (80 mg/kg) and sacrificed after
2 hr. Grafts were harvested and stained with Brdu antibody
(Figure 2B and Figure S3). The Brdu-labeled epithelia were
counted and averaged in four independent high-power
fields on each end of the two adjacent grafts as well as
the middle portion.
Two obviously distinct histologic zones were identified
when an FGF10-secreting graft was placed adjacent to
a normal graft (Figure 2B). One end of the graft with normal
UGSM showed normal prostatic tubules, while the oppo-
site end with FGF10-secreting mesenchyme revealed
well-differentiated adenocarcinoma (Figure 2B). FGF10
led to a local increase in the number of proliferating epithe-
lial cells, as shown by increased epithelial Brdu uptake in
the FGF10-containing region (Figure S3). The amount of
Brdu uptake was 5-fold less on the control side compared
to the cancer side of the graft, suggesting that the effects
of FGF10 were localized (Figure S3).
Decreasing the number of FGF10-secreting UGSM led
to a less severe phenotype, suggesting that the transform-Caning effects of paracrine FGF10 are dose dependent
(Figure 2C). In the presence of 50% FGF10 UGSM adeno-
carcinoma was noted, whereas progression to PIN adja-
cent to possibly microinvasive carcinoma (1:10) and PIN
(1:100) were observed in FGF10-diluted grafts, culminat-
ing in normal prostatic epithelium when the FGF10-secret-
ing mesenchymal cells were diluted by a factor of 1000.
Microinvasive adenocarcinoma and hyperplastic tubules
appeared adjacent to PIN lesions and normal prostate
glands in 1:10 and 1:100 diluted samples. This disease
pattern resembled the heterogeneous histologic appear-
ance of human prostate cancer and PIN (Figure 2C). To
examine the location of FGF10-secreting UGSM cells,
the expression of GFP was examined as an indirect
marker for FGF10, in the diluted 1:10 and 1:100 specimens
(Figures 2Da–2Dl). We observed the presence of GFP-
positive, hence FGF10-secreting, UGSM cells adjacent
to areas of microinvasive carcinoma and PIN lesions (Fig-
ures 2Dc, 2Dd, 2Di, and 2Dj). The expression of GFP was
noted to be absent adjacent to normal regenerated
tubules (Figures 2De, 2Df, 2Dk, and 2Dl).
Our data indicate that regional PIN and multifocal
adenocarcinoma could be recapitulated by altered adja-
cent cancer stromal cells, similar to the paracrine effects
of FGF10-overexpressing mesenchyme.
Inhibition of FGFR1 Signaling by DN FGFR1
Reverts FGF10-Induced Adenocarcinoma
We hypothesized that blocking FGFR1 and/or FGFR2
signaling would lead to formation of normal tubules even
in the presence of excess mesenchymal FGF10. To test
our hypothesis, lentiviral vectors were constructed to
express DN FGFR1 and DN FGFR2, flag tagged for better
detection on western blot (Figure 3A) (Li et al., 1994). The
DN FGFR1 and DN FGFR2 constructs encode proteins
that are truncated downstream of the transmembrane
domain and are signaling defective (Li et al., 1994). The
lentiviral constructs express the red fluorescent protein
(RFP) to mark the site of expression of the DN FGFR. Dis-
sociated prostate epithelial cells were infected with either
vector control, DN FGFR1, or DN FGFR2 and combined
with equal numbers of FGF10 and WT UGSM and grafted
for 6–8 weeks.
Expression of either DN construct resulted in formation
of smaller grafts compared to vector control (Figure 3B).
Fluorescence microscopy of the regenerated grafts was
performed. The frequency of red tubules composed of
DN FGFR1 or DN FGFR2 was significantly lower com-
pared to vector control. Multiple sections of regenerated
tissue were reviewed to identify relatively rare red tubules
in the grafts containing DN FGFR1 or DN FGFR2. The
decrease in the size and the rarity of red tubules in the
DN-regenerated tissue can be explained by the variation
in the copy number and integration frequency of lentiviral
DN constructs in the regenerating epithelia. High doses of
either of the DN constructs in the single prostate epithelial
cells could inhibit the regeneration into prostatic tubules,
and low copy numbers of the lentiviral vector could not
be visualized by microscopy. Therefore, the histologiccer Cell 12, 572–585, December 2007 ª2007 Elsevier Inc. 575
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Stromal FGF10-Induced Multifocal Prostate CancerFigure 2. Paracrine FGF10 Signaling
Promoted Formation of Multifocal Pros-
tate Cancer Resembling Human PIN or
Prostate Cancer and Exerted Its Effects
with Regional Specificity
(A) Schematic representation of two adjacent
grafts, one with FGF10 UGSM (1 3 105) and
a second graft with normal UGSM (1 3 105)
both combined with WT epithelium.
(B) Histology of two adjacent grafts revealed
normal prostate tubules on one side and well-
differentiated prostate cancer on the other
side, suggesting localized action of paracrine
FGF10.
(C) H&E analysis of regenerated tissue after
a logarithmic reduction in the number of
FGF10 UGSM revealed evidence of multifocal
carcinoma. Cancer was seen in (Ca) and (Cb),
PIN was seen adjacent to microinvasive carci-
noma in (Cc) and (Cd), multifocal PIN was seen
in (Ce) and (Cf), and predominantly normal
histology was seen in (Cg) and (Ch).
(D) Expression of FGF10 indirectly detected by
anti-GFP staining in areas of hyperplasia.data gathered in this experiment were on the group of cells
expressing intermediate copy numbers of the DN con-
structs, visualized by the expression of RFP.
Regenerated red cells expressing DN FGFR1 were
mostly confined within simple glandular and tubular struc-
tures resembling normal prostatic epithelial glands
(Figure 3C). These observations were confirmed in four
independent experiments. The majority of control RFP or
DN FGFR2 red cells were confined within clearly identifi-576 Cancer Cell 12, 572–585, December 2007 ª2007 Elsevier Iable glands and tubular structures that showed tufting
and extension into the glandular lumens, suggestive of
epithelial hyperplasia and/or PIN (Figure 3C). The degree
of tufting and hypercellularity noted in the DN FGFR2-
regenerated glands was less compared to control RFP
tissue in some regions. This finding suggests a partial
blocking effect resulting from the DN FGFR2 expression,
which may be due to nonspecific heterodimerization
with FGFR1 (Dailey et al., 2005).nc.
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levels of all other predominant binding partners for
FGFR1 (Zhang et al., 2006), in addition to FGF7 (a homolog
of FGF10) were not altered significantly (table in Fig-
ure S4B) when comparing WT to FGF10 UGSM. These
findings rule out the possibility of an FGF10-induced
FGF circuitry.
These data suggest that mesenchymal FGF10 predom-
inantly exerted its effects through epithelial FGFR1 and
validates previous data demonstrating that activation of
FGFR1 plays an important role in neoplastic transforma-
tion of prostate epithelium (Freeman et al., 2003). Our
data also demonstrate that inhibition of FGFR1 signaling
in prostate epithelium reverses the neoplastic phenotype
even in a high-FGF10 microenvironment.
Figure 3. FGF10 Induces Prostate Cancer Predominantly by
Activation of FGFR1
(A) The lentivirus FU-CRW vector used for the expression of flag-
tagged DN FGFR1 and DN FGF R2. Western blot confirmed the
expression of both dominant-negative constructs.
(B) Comparative analysis of graft weights (mean ± SD) regenerated
with control vector RFP, DN FGFR1-RFP, or DN FGFR2-RFP and com-
bined with FGF10 (5 3 104) added to WT (5 3 104) UGSM.
(C) Immunofluorescent analysis of grafts regenerated with vector con-
trol RFP, DN FGFR1-RFP, or DN FGFR2-RFP. DN FGFR1-RFP-
infected tubules showed cells completely confined within simple glan-
dular and tubular structures suggestive of normal prostate epithelium
in contrast to RFP or DN FGFR2-RFP-regenerated glands.CancEnhanced Paracrine Mesenchymal FGF10 Leads
to an Increase in Epithelial Androgen Receptor
Multiple in vitro but no in vivo studies demonstrate the
overexpression or activation of androgen receptor (AR)
by fibroblast growth factor peptides. In vitro studies
have shown that growth factors such as KGF can stimu-
late messenger RNA levels of AR in the absence of andro-
gens (Planz et al., 2001). IGF-I, EGF, and KGF can activate
AR in the absence of androgens, suggesting that these
growth factors can directly activate the androgen signal-
ing pathway (Culig et al., 1994).
To examine the effects of paracrine FGF10 on the expres-
sion of AR in our model, western blot analysis was performed
on protein lysates obtained from regenerated grafts. Densi-
tometry showed a roughly 4-fold increase in AR when
comparing FGF10- to control-regenerated grafts (Figure 4A).
Immunohistochemistry was performed to localize the
expression of AR. We determined that the majority of
epithelial cells in the FGF10 grafts strongly expressed
nuclear AR (Figures 4B). The level of AR protein expres-
sion was higher in the glandular epithelium of FGF10-
regenerated grafts compared to controls, as observed
by the relative intensities of AR staining (Figure 4B).
Similar to other steroid hormones, AR undergoes post-
translational modifications that can culminate in an in-
crease both in stability and activity of this receptor (Faus
and Haendler, 2006). Signaling through growth factor
receptors is one mechanism by which these posttransla-
tional modifications can be achieved (Reddy et al., 2006).
Quantitative PCR revealed that mRNA levels of AR,
obtained from epithelia exposed to paracrine FGF10, are
not dramatically altered compared to control-regenerated
epithelium (data not shown). These results suggest that
the FGF10-induced increase in epithelial AR maybe medi-
ated at a posttranslational level.
Figure 4. Paracrine FGF10 Resulted in an Increase in Epithe-
lial AR
(A) Western blot revealed a 4-fold increase in expression of AR protein
in FGF10- compared to control-regenerated grafts.
(B) Immunohistochemistry confirmed that paracrine FGF10 induced an
increase in glandular epithelial AR compared to control-regenerated
tissue.er Cell 12, 572–585, December 2007 ª2007 Elsevier Inc. 577
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Independent Survival and Proliferation
of Cancer Cells
Signaling through growth factor receptors can promote
androgen-independent growth of prostate cancer cells
by amplification of AR, an increase in the activation of
existing AR, modulation of coactivators/corepressors,
and posttranslational modifications that stabilize AR
(Feldman and Feldman, 2001).
To assess whether FGF10-induced adenocarcinoma
survives following withdrawal of androgen, animals har-
boring grafts composed of FGF10 or control mesenchyme
were castrated and followed for 6 weeks. Histologic anal-
ysis of the FGF10 grafts harvested from castrate animals
revealed persistence of well-differentiated prostate ade-
nocarcinoma (Figures 5Aa–5Ac). In contrast, in the WT
mesenchyme regenerated tissue, there was loss of
many epithelia with a remaining, depleted-appearing glan-
dular architecture (Figures 5Ad–5Af). Our results suggest
that the FGF10-induced prostate adenocarcinoma cells
harbor survival mechanisms that allow proliferation and
survival in castrate levels of androgen.
Immunohistochemistry was performed to compare the
localization and expression of AR in the intact versus
castrate FGF10 grafts (Figure 5B). The glandular tissue
of the intact FGF10 grafts expressed high levels of nu-
clear AR (Figures 5Ba and 5Bb). Castration led to partial
cytoplasmic translocation of AR in the FGF10-regener-
ated tissue (Figures 5Bc and 5Bd). However, partial nu-
clear localization of AR persisted in the majority of the
FGF10 glandular epithelium, and there were foci that con-
tinued to harbor strong nuclear expression of AR (Figures
5Bc and 5Bd).
To assess the acute and chronic effects of androgen
withdrawal on proliferation and apoptosis in FGF10-
regenerated tissue, animals harboring FGF10 mesenchy-
mal grafts were castrated, and grafts were harvested at
1 and 6 weeks. Castrated grafts were half the size of grafts
harvested from intact animals at 6 weeks (Figure 5C). We
quantified the proliferation index at 6 weeks, and rate of
apoptosis at 1 week postcastration using Ki67 immuno-
histochemistry and TUNEL assays, respectively (Figures
S5A and S5B). We counted and averaged the Ki67-
or TUNEL-positive epithelia in five high-power micro-
scopic fields. A decrease in proliferation measured by
the percentage of Ki67-positive cells (8% in intact versus
4% in castrate), which did not reach statistical signifi-
cance, and a statistical significant increase in apoptosis
measured by the percentage of TUNEL-positive cells
(0.8% in intact versus 1.6% in castrate) was seen upon
castration (Figures S5A and S5B).
Decrease in the size of the grafts, increase in apoptosis,
and decrease in proliferation upon castration suggest that
a subset of the FGF10-induced adenocarcinoma remains
dependent on androgen hormone. Persistence of the
remaining FGF10-induced prostate adenocarcinoma cells
and Ki67 staining suggests that paracrine FGF10 signaling
can promote survival and proliferation of these cells in
castrate levels of androgen. The dramatic increase in AR578 Cancer Cell 12, 572–585, December 2007 ª2007 Elsevier IFigure 5. Paracrine FGF10 Promoted Androgen-Independent
Survival of a Subset of Prostate Adenocarcinoma
(A) Histology of the FGF10 and WT mesenchyme regenerated grafts
harvested from castrated animals. Loss of many epithelia was ob-
served in WT grafts. In contrast, persistence of adenocarcinoma cells
was noted in all five FGF10-regenerated specimens.
(B) Immunohistochemical localization of AR in FGF10 grafts obtained
from intact and castrated animals. Castration led to partial cytoplasmic
transport of AR in castrate (Bc and Bd) compared to intact (Ba and Bb)
grafts. Partial nuclear localization of AR persisted despite castration in
the FGF10-regenerated tissue (Bc and Bd).
(C) Comparative analysis of weight (mean ± SD) of grafts harvested
from intact and castrate animals.nc.
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tivity to residual castrate levels of androgens may be one
survival strategy used by the surviving cancer cells after
castration. Androgen-independent activation of AR by
paracrine FGF10 may be an alternate mechanism leading
to androgen-independent survival of a subset of the
FGF10-induced adenocarcinoma.
A Subset of FGF10-Induced PIN or
Adenocarcinoma Is Serially Transplantable
While chronic signaling through an oncogenic pathway is
essential for maintaining transformation in some malig-
nancies, cell-autonomous alterations can be sufficient to
bypass this continual dependence in other cancer models
(Weinstein, 2002). We assessed whether transformation of
epithelia exposed to FGF10 would evade or remain
dependent on chronic paracrine signaling by this growth
factor and asked whether the FGF10-induced adenocar-
cinoma was serially transplantable. Prostate epithelium
from DS red transgenic animals were recombined with
FGF10-GFP UGSM and placed in the regeneration sys-
tem. DS red transgenic animals were used as they express
the red fluorescent protein variant DS Red, providing
a fluorescent marker for the epithelia. Grafts were har-
vested following 8 weeks of regeneration, minced, and
digested into single cells.
Dilution of FGF10-UGSM cells by a factor of 1000 would
lead to formation of normal tubules in this regeneration
system (Figure 2C). DS red dissociated single cells (2 3
104) harvested from FGF10-regenerated grafts were com-
bined with WT epithelium (2 3 104) and an excess of WT
mesenchyme such that the number of FGF10-expressing
mesenchymal cells would be diluted by a factor of 1000.
These cells were engrafted as a secondary tumor. After
8 weeks of regeneration, histologic analysis revealed
areas of WT epithelium adjacent to hyperplastic foci of
cells with uniform epithelial tufting, crowding, and nuclear
atypia (Figures S6Aa–S6Ac). Immunofluorescent micros-
copy revealed WT and red tubules forming double-layered
large tubules with normal architecture adjacent to red
clusters of glands filled with several layers of tufted epithe-
lial cells, reminiscent of PIN (Figures S6Ad–S6Af). This
observation suggested that the FGF10-induced PIN could
persist in an FGF10-low microenvironment.
DS red dissociated single cells harvested from FGF10-
regenerated grafts were FACS sorted (R1), assuring exclu-
sion of single or doublets of GFP-positive cells (R2 + R3)
(Figure 6A). DS red sorted cells (3 3 104) were either
recombined with WT epithelia (7 3 104) as helper cells,
or engrafted alone with WT UGSM cells (105) as a second-
ary tumor in the regeneration system. Histologic analysis
of grafts with added helper cells revealed multiple normal
tubules, in addition to areas demonstrating cellular tufting,
crowding, and few foci with crowded microglandular
structures containing cells with atypical nuclear features
and higher nuclear-to-cytoplasmic ratios (Figures 6Aa
and 6Ab). Immunofluorescent microscopic evaluation of
this regenerated tissue revealed formation of some dou-
ble-layered large red tubules resembling normal glandsCan(Figures 6Ba and 6Bb), in addition to other areas demon-
strating small clusters of red tubules reminiscent of well-
differentiated adenocarcinoma (Figure 6Bc and 6Bd).
Our findings suggest that an 8 week exposure to para-
crine FGF10 may induce a subset of epithelial cells to
continuously form abnormal epithelial structures, archi-
tecturally ranging from hyperplasia to well-differentiated
adenocarcinoma, even in low levels of this growth factor.
To test whether the FGF10-induced adenocarcinoma is
serially transplantable, we dissociated secondary grafts
into single cells and retransplanted them into a tertiary
graft (Figure S6B). In these tertiary grafts, similar to the
primary and secondary tumors, we observed abnormal
epithelial structures architecturally ranging from epithelial
hyperplasia to well-differentiated adenocarcinoma, sug-
gesting that a subset of FGF10-induced PIN/adenocarci-
noma is serially transplantable (Figure S6B). The rate of
proliferation of the transplanted secondary and tertiary
tumors was found to be similar to the primary FGF10
grafts and significantly more than normal regenerated tis-
sue assessed and quantified by Ki67 staining (Figure S7).
To ascertain possible mechanisms that could account
for this sustained oncogenic phenotype, in low levels of
FGF10, transplanted DS red regenerated tissue (without
helper cells) were evaluated for phosphotyrosine activa-
tion in secondary and tertiary tumors. Immunohistochem-
ical analysis of the transplanted tissue with pan-phos-
photyrosine antibody revealed strong phosphotyrosine
activation in cancerous regenerated glands (Figures 6Cc,
6Cd, 6Cg, and 6Ch; Figure S8B). In these histologic spec-
imens, the absence of GFP staining further confirmed the
exclusion of exogenous growth factor-expressing UGSM
cells (Figures 6Cb and 6Cf). Regenerated tissue with nor-
mal UGSM was used as a negative control, and cancerous
tissue with FGF10 UGSM was used as positive control in
assessing phosphotyrosine activity (Figure S8B). Sus-
tained nuclear localization of AR was seen in secondary
and tertiary transplanted regenerated tissue, demonstrat-
ing sustained activation of the AR machinery (Figures 6Da
and 6Db; Figure S8A).
Cooperation between Mesenchymal FGF10
and Cell-Autonomous AKT Leads
to High-Grade Carcinoma
We sought to evaluate the biological consequences of
combining two events in naive prostate epithelial cells,
‘‘outside-in’’ signaling through mesenchymal FGF10 and
cell-autonomous expression of activated AKT. We had
previously shown that chronic activated epithelial AKT
could lead to the formation of PIN, while the combination
of epithelial AKT and AR would lead to the formation of
carcinoma (Xin et al., 2006). In this model, paracrine
FGF10 signaling led to an increase in epithelial AR. We
asked whether paracrine FGF10 signaling could synergize
with cell-autonomous activated AKT.
Prostate single cells were infected with control vector or
activated AKT and combined with either FGF 10 express-
ing UGSM or vector control UGSM and placed in the
regeneration system. Grafts were harvested after 7 weekscer Cell 12, 572–585, December 2007 ª2007 Elsevier Inc. 579
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set of FGF10 Induced Adenocarcinoma
(A) Schematic representation of transplanta-
tion experiments and histology of regenerated
tubules.
(B) Immunofluorescent analysis of regenerated
tissue revealed formation of many WT and
some red epithelial glands with a single cell
layer resembling normal tubules (Ba and Bb),
and multiple small red tubules adjacent to nor-
mal-appearing WT glands reminiscent of well-
differentiated adenocarcinoma (Bc and Bd).
(C) Histologic evaluation of transplanted tissue
specimens revealed evidence of adenocarci-
noma (Ca and Ce) and absence of contaminat-
ing FGF10-expressing stromal cells demon-
strated by lack of GFP staining (Cb and Cf).
The cancerous regenerated tissue revealed
strong phosphotyrosine activation after with-
drawal of retrovirally infected FGF10 UGSM
cells (Cc, Cd, Cg, and Ch).
(D) Persistent strong nuclear localization of AR
was observed in cancerous areas of the trans-
planted regenerated grafts (Da and Db).and weighed (Figure 7A), and the histology was evaluated
(Figures 7Ba–7Bf). Addition of epithelial AKT to mesen-
chymal FGF 10 more than doubled the size of the grafts
as compared to grafts with epithelial AKT alone (Fig-
ure 7A). The combination of AKT and FGF10 resulted
in grafts that were six times the weight of grafts with
FGF10 alone (Figure 7A). Histologic analysis of the 3/3
regenerated grafts revealed areas of poorly differentiated
adenocarcinoma with mesenchymal FGF10 and epithelial580 Cancer Cell 12, 572–585, December 2007 ª2007 Elsevier IAKT, defined by sheets of atypical cells with almost com-
plete loss of glandular architecture (Figures 7Bc and 7Bf;
Figure S9). Mesenchymal FGF10 led to the development
of well-differentiated adenocarcinoma (Figures 7Ba and
7Bd), and epithelial AKT alone led to PIN defined by strat-
ification of epithelial cells with nuclear atypia confined
within glandular structures (Figures 7Bb and 7Be). Expres-
sion of epithelial phospho-AKT was confirmed using
immunohistochemistry (Figures 7Bh and 7Bi). Stromalnc.
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gized with Cell-Autonomous AKT Lead-
ing to a Progressive Cancer Phenotype
and a Dramatic Increase in Epithelial AR
(A) Transilluminating images and comparative
weight (mean ± SD) of grafts derived from WT
epithelium with FGF10 UGSM, AKT epithelium
with WT UGSM and AKT epithelium with
FGF10 UGSM.
(B) H&E staining for the regenerated tissue de-
rived from WT epithelium with FGF10 UGSM
(Ba and Bd), AKT epithelium with WT UGSM
(Bb and Be) and AKT epithelium with FGF10
UGSM (Bc and Bf). Immunohistochemical
analysis of the expression phospho-AKT (Bg–
Bi) and GFP (Bj–Bl).
(C) Western blot analysis with AR antibody
confirmed the increase in AR in the presence
of mesenchymal FGF10. Vinculin used as load-
ing control.
(D) Immunofluorescence detection of AR re-
vealed that FGF10 mesenchyme in combina-
tion with WT or AKT activated epithelium could
lead to an increase in expression of epithelial
AR compared to controls.expression of FGF10-GFP or GFP was confirmed by
immunohistochemical detection of GFP (Figures 7Bj–
7Bl). Our data demonstrate synergy between paracrineCancFGF10 signaling and cell-autonomous AKT, implicating
the importance of cooperation between stromal and
epithelial perturbations in malignant transformation.er Cell 12, 572–585, December 2007 ª2007 Elsevier Inc. 581
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between paracrine mesenchymal FGF10 and cell-autono-
mous AKT, regenerated grafts were lysed for western blot
analysis (Figure 7C). We had previously observed a 4-fold
increase in the expression of AR comparing FGF10 to con-
trol grafts (Figure 4A). Similarly, densitometry on western
blots showed roughly an 8-fold increase in AR protein
when comparing grafts composed of epithelial AKT com-
bined with mesenchymal FGF10 to grafts composed of
epithelial AKT alone (Figure 7C). Immunohistochemistry
confirmed that AR was mainly overexpressed in the
epithelial compartment (Figures 7Da and 7Db compared
to 7Dc and 7Dd and Figures 7De and 7Df compared to
7Dg and 7Dh).
These data indicate that paracrine FGF10 signaling
leads to an increase in epithelial AR, and this secondary
event can cooperate with activated epithelial AKT, leading
to a progressive cancer phenotype.
DISCUSSION
Historically, essential growth factors have proven to be
oncogenic in multiple tumor models (Kris et al., 1985).
For example, platelet-derived growth factor, an essential
peptide for wound healing, was one of the first described
growth factor oncogenes (Doolittle et al., 1983). We have
demonstrated that enhanced expression of stromal
FGF10, an essential gene for prostate development, is
sufficient for the formation of multifocal adenocarcinoma
concomitant with an increase in epithelial AR in an
in vivo prostate cancer model.
Similar to FGF10, AR is essential for the development of
the prostate (Cunha and Lung, 1978). We show that
enhanced expression of stromal FGF10 is sufficient to
increase levels of AR protein in both naive and activated
AKT prostate epithelium. Interestingly, in our study, ex-
pression of additional AR in WT epithelium using lentiviral
delivery vectors in combination with mesenchymal FGF10
led to no discernable histologic difference compared to
mesenchymal FGF10-regenerated grafts (Figures S10A
and S10B). Developmental studies using in vitro organ
culture systems of FGF10 null prostate demonstrate that
addition of exogenous FGF10 can induce branching mor-
phogenesis similar to the addition of testosterone, while
addition of both FGF10 and testosterone do not provide
further synergistic effects (Thomson and Cunha, 1999).
Our findings concur with previous observations and sug-
gest that paracrine FGF10 signaling can promote activa-
tion of AR. An increase in AR protein may be one mecha-
nism by which this overactivation is achieved.
Amplification of the AR gene has been reported in up to
30% of human prostate cancers and is thought to be an
important mechanism for formation of androgen indepen-
dence (Chen et al., 2004; Feldman and Feldman, 2001).
Perturbations in the growth factor regulatory loops are as-
sociated with progression to a more aggressive cancer
phenotype leading to androgen-independent metastatic
disease (Culig et al., 2000, 2002; Scher et al., 1995). In
our model, survival of a subset of the FGF10-induced582 Cancer Cell 12, 572–585, December 2007 ª2007 Elsevier Inprostate adenocarcinoma cells, concomitant with partial
nuclear localization of AR in the castrate tumors, suggests
activation of AR signaling axis by paracrine mesenchymal
FGF10 in castrate levels of androgen.
Transformed cells, such as Bcr-Abl-induced leukemia
(Huettner et al., 2000) or ras-induced melanoma (Chin
et al., 1999), are found to be ‘‘addicted’’ to oncogenic sig-
nals, such that removal of the activating signal can lead to
regression of the cancer phenotype (Weinstein, 2002). It is
conceivable that a subset of cells exposed to an onco-
gene may undergo subsequent genetic alterations allow-
ing them to evade chronic dependence on the initial
growth-promoting activated pathway (Weinstein, 2002).
This phenomenon is seen in a subpopulation of c-myc-
induced mammary carcinoma cells that can continue to
grow in a myc-independent manner after downregulation
of this oncogene (Boxer et al., 2004). Formation of PIN
or adenocarcinoma in transplanted epithelia, previously
exposed to high levels of FGF10, suggests a possible
‘‘hit and run’’ mechanism for the paracrine FGF10-
induced epithelial alterations. Persistence of pan-phos-
photyrosine kinase activity and sustained nuclear localiza-
tion of AR in this subset of transplanted cancerous tissue
suggests intrinsic genetic alterations, resulting in survival
and growth of this subpopulation of cells in low levels of
FGF10. The nongenotropic activity of AR has been linked
to activation of several tyrosine kinases including the Src,
PI3 kinase (phosphoinositide 3- kinase), and MAPK kinase
(mitogen-activated protein kinase) family receptors (Kous-
teni et al., 2001; Sun et al., 2003). Conversely, activation of
protein tyrosine kinases can lead to activation of the AR
(Feldman and Feldman, 2001). Either of these mecha-
nisms, in conjunction or solely, could account for the
sustained cancerous phenotype noted in the transplanted
grafts.
Cancer progression can result from the accumulation of
multiple cooperative genetic events, a concept that has
been demonstrated in three recent prostate cancer
models (Gao et al., 2006; Xin et al., 2006; Zhong et al.,
2006). Cooperation between autocrine FGFR signaling
and the PI3 Kinase pathway was shown in an in vivo trans-
genic animal model in which loss of PTEN and overexpres-
sion of FGF8b in the epithelium led to poorly differentiated
adenocarcinoma (Zhong et al., 2006). We had previously
shown synergy between epithelial AR and AKT resulting
in adenocarcinoma that resists the effects of androgen ab-
lation (Xin et al., 2006). Loss of PTEN and Nkx3.1 is another
mechanism that can promote androgen-independent
prostate carcinoma (Gao et al., 2006). Our study empha-
sizes synergy between a paracrine growth factor,
FGF10, and epithelial cell-autonomous activated AKT.
This model emphasizes the importance of stromal para-
crine and epithelial cell-autonomous signals leading to
the development of poorly differentiated disease.
These data suggest the importance of targeting the
growth factor receptor signaling axis through either inhibi-
tion of paracrine factors or direct inhibition of growth
factor receptors, in conjunction with other therapeutic
strategies, such as androgen ablation used in treatingc.
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cades similar to fibroblast growth factors may also delay
emergence of androgen hormone independence, which
poses the largest clinical challenge in the treatment of
prostate cancer.
EXPERIMENTAL PROCEDURES
Plasmids
cDNA encoding FGF10 was procured by RT-PCR, from NIH 3T3 cells,
and cloned into the EcoRI site of MSCV-IRES-GFP (MSCV, murine
stem cell virus; IRES, internal ribosomal entry site) (Hawley et al.,
1994). DN FGFR1 and DN FGFR2 (Li et al., 1994) were flag tagged
and subcloned into the EcoRI cloning site of FU-CRW lentiviral expres-
sion vector. FU-CRW is a vector derived from FUGW (Xin et al., 2006).
In the FU-CRW vector the GFP coding sequence of FUGW vector was
substituted with a CMV-driven RFP expression cassette. Myristoy-
lated human AKT1 was subcloned into the EcoRI site of FU-CRW
lentiviral expression vector.
Prostate Regeneration and Prostate Epithelial
Viral Infections
The details of the regeneration process and viral infection of epithelial
cells have been explained previously (Xin et al., 2003). Housing, main-
tenance, and all surgical procedures were undertaken in compliance
with the regulations of the Division of Laboratory Animal Medicine of
the University of California, Los Angeles. All experimental procedures
were approved by the Division of Laboratory Animal Medicine of the
University of California, Los Angeles. Viral preparation procedures
were performed under University of California, Los Angeles, safety reg-
ulations for lentivirus usage. Retrovirus and lentivirus were made as
described previously (Wong et al., 2004; Xin et al., 2003, 2006).
Immunohistochemistry
Grafts were fixed in buffered formalin 10% and placed in 70% ethanol
as described previously (Xin et al., 2003, 2006). Sections (4 mm) were
made and stained with hematoxylin and eosin (H&E) or with antibodies
against CK5 (AF138, Abcam), P63 (sc-8431, Santa Cruz Biotechnol-
ogy), E-cadherin (610-182, Transduction), anti-AR (sc-816, Santa
Cruz Biotechnology), P AKT (3787, Cell Signaling), GFP (mouse mono-
clonal clone 3C2-G2 produced in O.N.W.’s labs), anti-Brdu (51-75512
PharMingen), pan-phosphotyrosine (Upstate), CK8 (MMS-162P Cova-
nce), and Ki67 (Vector) antibodies. For visualization of CK5, E-cad-
herin, AR, pAKT biotinylated anti-mouse IgG (RO627, Vector Biotech-
nology), and biotinylated anti-rabbit IgG (ab6720-1, Abcam) secondary
antibodies were used. Histologic sections were visualized with fluores-
cent microscopy and counterstained with DAPI (Vector Laboratories).
Western Blot
Grafts and cells were manually lysed in RIPA buffer composed of
50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% SD, 1%
NP-40, 1 mM EDTA, 1 mM PMSF, 25 mM NaF, cocktail protease inhib-
itors (Roche), and phosphatase inhibitor 1 and 2 (Sigma). Secreted
FGF10 protein was collected and precipitated from a 48 hr low serum
cultured media collected from UGSM cells expressing FGF10 at a 4:1
ratio with 50% TCA (trichlor acetic acid), centrifuged, pelleted, washed
with acetone, air dried, and resuspended with 23 SDS lysis buffer. pH
was adjusted with 10 M NaOH. Protein lysates (40–100 mg) were sep-
arated by SDS-PAGE followed by western blot analysis using AR (sc-
816, Santa Cruz Biotechnology), FGF10 (sc-Santa Cruz Biotechnol-
ogy), Vinculin (Sigma), anti-flag (Sigma), and Erk2 (sc-154, Santa
Cruz Biotechnology) antibodies. Quantification of the western blot
data was performed using the NIH ImageJ program (http://rsb.info.
nih.gov/ij/).CanQuantitative RT-PCR
Quantitative RT-PCR was performed using an ABI 7700 Real Time
PCR System. Primers are listed in the table in Figure S4A. All primers
span at least one intron. Standard curves of murine placenta cDNA
were run for each primer pair, and the amount of target gene was
normalized to the amount of actin.
Supplemental Data
The Supplemental Data include ten supplemental figures and can be
found with this article online at http://www.cancercell.org/cgi/
content/full/12/6/572/DC1/.
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